Equities

F D C Ltd

F D C Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)536.20
  • Today's Change-5.65 / -1.04%
  • Shares traded143.21k
  • 1 Year change+42.99%
  • Beta0.7026
Data delayed at least 15 minutes, as of Oct 11 2024 11:21 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

FDC Limited is an India-based company, which is principally engaged in the business of pharmaceuticals. The Company manufactures and distributes its range of generics, formulations, and active pharmaceuticals at its manufacturing plants. It also manufactures oral rehydration salts (ORS) and specialized formulations. It has a range of functional foods and beverages. Its active pharmaceutical ingredients (APIs) include Albuterol Sulfate, Bromhexine Hydrochloride, Cinnarizine, Flunarizine Dihydrochloride, Flurbiprofen, Flurbiprofen Sodium, Miconazole Nitrate and Timolol Maleate, among others. It has its presence in various therapeutic segments, such as anti-infectives, gastrointestinal, ophthalmological, vitamins/ minerals/ dietary supplements, cardiac, anti-diabetes, respiratory, gynecology, dermatology, analgesics, and others. Its various brands include Zifi, Electral, Enerzal, Vitcofol, Pyrimon, Zocon, Zoxan, Zathrin, Zipod, Zefu, Cotaryl and Mycoderm.

  • Revenue in INR (TTM)20.45bn
  • Net income in INR3.14bn
  • Incorporated1940
  • Employees6.66k
  • Location
    F D C Ltd142-148, S.V. Road, Jogeshwari (W)MUMBAI 400053IndiaIND
  • Phone+91 2 226739100
  • Fax+91 2 226300614
  • Websitehttps://www.fdcindia.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Supriya Lifescience Ltd5.99bn1.35bn45.46bn448.0033.62--29.957.5916.8016.8074.42--------13,370,000.00--19.08--24.0462.7557.1222.5824.71--92.47--2.8823.7415.4732.5624.7583.79--
RPG Life Sciences Limited6.00bn923.20m46.42bn1.27k50.28--42.027.7455.8255.82362.60--------4,721,969.00--16.07--21.7768.4262.9915.3911.99--220.43--29.2713.5012.0129.6051.9828.6046.14
Aarti Drugs Ltd24.23bn1.57bn46.54bn1.06k29.85--22.251.9217.0817.08263.82--------22,770,740.00--9.73--15.7834.3222.236.488.25--7.28-----6.9010.133.0713.8224.96--
Morepen Laboratories Ltd17.45bn1.18bn47.98bn1.62k37.90--32.072.752.312.3134.26--------10,749,300.00--7.90--13.3437.8633.346.775.49--33.34--0.0019.2517.08148.6327.2247.03--
SeQuent Scientific Ltd14.27bn54.87m48.02bn1.20k901.99--61.823.370.21370.213757.18--------11,939,190.00--1.09--1.7645.3841.970.99021.18--0.9009--35.06-3.605.6870.40--6.96--
Unichem Laboratories Ltd17.28bn-605.50m50.04bn3.19k----95.772.90-8.59-8.59245.15--------5,410,587.00---1.67---2.0362.0056.18-3.50-3.99--0.1401----26.947.6465.15---35.00--
Aarti Pharmalabs Ltd19.50bn2.25bn54.96bn1.63k24.40--18.232.8224.8624.86215.17--------11,983,730.00--------44.20--11.55----18.55-----4.76--12.10------
Sun Pharma Advanced Research Co Ltd684.05m-3.89bn69.18bn409.00------101.13-11.97-11.972.11--------1,672,501.00---61.70---119.3159.8174.49-568.24-163.40---208.33-----68.36-16.21-73.96--15.40--
Orchid Pharma Ltd8.81bn1.12bn70.60bn872.0060.82--48.188.0222.8922.89180.65--------10,101,540.00---0.9734---1.4040.6740.7412.78-2.40--6.08----23.056.4373.595.8457.79--
Shilpa Medicare Ltd11.84bn447.57m85.31bn931.00174.64--55.737.215.005.00133.55--------12,716,850.00--2.84--3.6565.1960.083.797.03--1.56--10.769.669.44198.15-22.26-9.26--
Procter & Gamble Health Ltd11.51bn2.01bn86.90bn1.41k43.2616.1538.057.55121.01121.01693.20324.241.212.7111.45--21.21--29.28--71.29--17.46--1.90386.940.0175---6.37---12.42------
F D C Ltd20.45bn3.14bn87.30bn6.66k27.91--24.554.2719.2119.21124.56--------3,070,786.00--12.05--13.7365.5561.5415.3715.85--75.15--1.098.9212.2457.3012.4516.93--
Blue Jet Healthcare Ltd6.95bn1.57bn90.75bn447.0057.64--49.6113.069.089.0840.07--------15,547,110.00--------55.54--22.65----124.37-----1.30--2.33------
Sanofi Consumer Healthcare India Ltd8.01bn2.31bn112.90bn--48.9461.1648.1814.10100.17100.17347.6780.15----------------71.64--28.81--2.273,260.000.0986--------------
Data as of Oct 11 2024. Currency figures normalised to F D C Ltd's reporting currency: Indian Rupee INR

Institutional shareholders

9.51%Per cent of shares held by top holders
HolderShares% Held
ICICI Prudential Asset Management Co. Ltd.as of 13 Jun 20238.44m5.18%
Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 30 Jun 20244.30m2.64%
Dimensional Fund Advisors LPas of 04 Jul 2024890.35k0.55%
Bandhan Asset Management Co. Ltd.as of 30 Jun 2024492.22k0.30%
Tata Asset Management Pvt Ltd.as of 31 Jul 2024471.28k0.29%
SSgA Funds Management, Inc.as of 03 Jul 2024328.82k0.20%
BlackRock Fund Advisorsas of 04 Jul 2024288.21k0.18%
BlackRock Advisors (UK) Ltd.as of 04 Jul 2024148.04k0.09%
Mellon Investments Corp.as of 03 Jul 202466.39k0.04%
ITI Asset Management Ltd. (India)as of 15 Jul 202464.38k0.04%
More ▼
Data from 31 Mar 2024 - 08 Aug 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.